This is a menu of antibodies and probes available at PhenoPath Laboratories for clinical immunohistochemical or in situ hybridization studies. Our collection of available antibodies and probes continues to expand; please contact us if there is an antibody or probe that you are unable to locate. Please note that this list does not include antibodies or probes available for research studies.
| Target |
Useful Application/Cells/ Tumors Identified |
| A |
|
| ACTH |
Subset of pituitary tumors |
| Actin, muscle specific (HHF-35) |
Smooth, skeletal muscle differentiation: leiomyosarcoma, rhabdomyosarcoma, myofibroblasts, myoepithelium |
| Actin, smooth muscle alpha |
(1A4) Smooth muscle differentiation: leiomyosarcoma, myofibroblasts, myoepithelium |
| Adenovirus |
Adenovirus identification |
| ALK protein (p80) |
Anaplastic large cell lymphoma (subset with t(2;5)) |
| Alpha-1-antitrypsin |
Alpha-1-antitrypsin deficiency |
| Alpha-fetoprotein |
Yolk sac tumors, hepatocellular carcinoma |
| AMACR (p504s) |
Prostate carcinoma marker |
| Amyloid type analysis |
Amyloid P, Amyloid A, Transthyretin, Kappa, Lambda, Β-Amyloid, Congo Red, Β-2-Microglobulin |
| Amyloid A |
Subtype of amyloid |
| Amyloid beta |
Subtype of amyloid, Alzheimer disease |
| Amyloid P component |
Amyloid (all subtypes) |
| Androgen receptor |
Prognostic and predictive marker in prostate cancer |
| B |
|
| bcl-2 |
Nodular lymphoma v. reactive hyperplasia, subset of lymphomas, carcinomas, and sarcomas |
| bcl-6 |
Follicular lymphoma |
| Ber-Ep4 |
(Epithelial glycoprotein) Subset of adenocarcinoma, negative on mesothelioma |
| Beta-2-microglobulin |
Amyloid subtype |
| Beta-catenin |
Nuclear localization in colorectal adenocarcinoma and abdominal fibromatosis |
| Bg8 |
Blood group antigen (Lewis Y); subset of adenocarcinoma, negative on mesothelioma |
| ΒHCG |
See Chorionic gonadotropin |
| BK virus |
See SV40 |
| Blood group A |
Identification of tissue 'floaters' |
| Blood group B |
Identification of tissue 'floaters' |
| Blood group H (O) |
Identification of tissue 'floaters' |
| Bob-1 |
B cell transcription factor |
| C |
|
| C3 (complement) |
For skin immunofluorescence studies* |
| c-kit (CD117) |
Gastrointestinal stromal tumors, mast cells |
| CA-125 |
Not offered; see WT-1 |
| Calcitonin |
Thyroid C cells, medullary carcinoma |
| Caldesmon |
Endometrial stromal tumors vs. smooth muscle tumors |
| Calponin |
Myoepithelial marker, in situ v. infiltrating breast carcinoma |
| Calretinin |
Mesothelioma |
| Caspase 3 fragment |
Apoptotic cells |
| Cathepsin D |
Prognostic marker in breast cancer |
| CD1a |
Langerhans cells, histiocytosis X |
| CD2 |
T cell subset |
| CD3 |
Mature T cells, T cell lymphoma |
| CD4 |
T cell subset |
| CD5 |
T cells, mantle zone cells, small lymphocytic B cell lymphoma |
| CD7 |
T cell marker |
| CD8 |
T cell subset |
| CD10 (CALLA) |
Subset of lymphomas and carcinomas |
| CD15 |
Reed-Sternberg cells of Hodgkin lymphoma, neutrophils, some adenocarcinomas |
| CD20 |
B cell lymphomas, target of immunotherapy |
| CD21 |
B cell and follicular dendritic cells and tumors |
| CD22 |
B cell lymphomas, target of immunotherapy |
| CD23 |
Small lymphocytic (B cell) lymphoma |
| CD25 |
Lymphoid activation marker, target of immunotherapy |
| CD30 (K-1 antigen) |
Hodgkin disease, anaplastic large cell lymphoma, embryonal CA |
| CD31 |
Endothelial cells and tumors |
| CD34 |
Endothelium and endothelial tumors, leukemias, subset of mesenchymal tumors |
| CD35 |
Follicular dendritic cells and tumors |
| CD43 |
T cells, leukemias, macrophages, often coexpressed in B cell lymphomas |
| CD45 |
(Common leukocyte antigen, T200 antigen) Marker of lymphocytes, hematolymphoid processes |
| CD45-RO |
T cells, macrophages, granulocytic precursors |
| CD52 (CAMPATH 1H) (requires frozen tissue) |
T cells, B cells |
| CD56 (NCAM) |
Natural killer cells (NK/T cell lymphoma), neural tumors |
| CD57 |
Nerve sheath tumors, T cells in NLPHL |
| CD66 |
(CEA family) Adenocarcinoma subset, hepatocellular carcinoma (bile canalicular pattern), negative on mesothelioma |
| CD68 |
Macrophage marker |
| CD79a |
B cell lymphomas |
| CD99 |
PNET/Ewing tumors |
| CD117 (c-kit) |
Gastrointestinal stromal tumors, mast cells |
| CD138 |
Plasma cells and myeloma |
| CDX2 |
Colorectal adenocarcinomas and subset of other GI adenocarcinomas |
| CEA (CD66e) |
Adenocarcinoma subset, negative on mesothelioma |
| CEA family (CD66) |
Adenocarcinoma subset, hepatocellular carcinoma (bile canalicular pattern), negative on mesothelioma |
| Chlamydia |
Chlamydia identification (all species) |
| Chorionic gonadotropin |
(HCG, ΒHCG) Trophoblasts and choriocarcinoma |
| Chromogranin A |
Neuroendocrine differentiation |
| Collagen, type IV |
Basement membrane protein, subset of mesenchymal tumors |
| Common leukocyte antigen |
See CD45 |
| Complement C3 |
See C3 |
| COX-2 (cyclo-oxygenase-2) |
Predictor of treatment response |
| Cyclin D1 |
Mantle cell lymphoma |
| Cytokeratin 1/10 (34βB4) |
Squamous cell carcinoma |
| Cytokeratin 5 |
(CK 5/6) mesothelioma, squamous cell carcinoma, transitional cell carcinoma |
| Cytokeratin 7 |
Carcinoma subset |
| Cytokeratin 8 |
(Low MW cytokeratin) All non-squamous carcinomas |
| Cytokeratin 17 |
Carcinoma subset |
| Cytokeratin 19 |
Carcinoma subset |
| Cytokeratin 20 |
GI tumors, transitional cell carcinoma, Merkel cell tumors |
| Cytokeratin, high MW (34βE12) |
Carcinoma subset; normal or hyperplastic prostate v. prostatic carcinomas |
| Cytokeratins (pan) |
(OSCAR, AE1/AE3) All epithelial cells and all carcinomas |
| Cytomegalovirus |
CMV identification |
| D |
|
| D2-40 (Podoplanin) |
See Podoplanin |
| DBA.44 |
See Hairy cell leukemia |
| Desmin |
Skeletal, smooth muscle tumors |
| E |
|
| E-cadherin |
Positive on ductal, negative on lobular breast carcinomas |
| EBV (EBER1) |
(Via in situ hybridization) Post transplantation lymphoproliferative disorder, Hodgkin lymphoma, EBV identification |
| EBV - LMP |
LMP = Latent membrane protein of EBV |
| EGFR |
(Epidermal growth factor receptor) prognostic marker in certain carcinomas |
| EMA |
(Epithelial membrane antigen) Some carcinomas, meningioma, anaplastic large cell lymphoma |
| Epithelial glycoprotein (Ber-Ep4) |
Subset of adenocarcinomas, negative on mesothelioma |
| Estrogen receptor (ER) |
Prognostic and predictive marker in breast and other carcinomas |
| F |
|
| Factor VIII related antigen |
(von Willebrand factor) endothelial cells, megakaryocytes |
| Factor XIIIa |
Dermal dendrocytes, dermatofibroma |
| Fascin |
Hodgkin lymphoma |
| Filaggrin |
Squamous cell differentiation marker |
| FLI-1 |
Presence of EWS-FLI-1 fusion product secondary to (11;22) (q24;q12) translocation characteristic of PNET Ewing sarcoma |
| FSH |
Subset of pituitary tumors |
| G |
|
| Gastrin |
Subset of pancreatic islet cell tumors |
| GCDFP-15 (Brst2) |
Breast, salivary, sweat gland tumors |
| GFAP (Glial-fibrillary acidic protein) |
Glioma |
| Glucagon |
Subset of pancreatic islet cell tumors |
| Glycophorin A |
Erythroid marker |
| Glypican-3 (GPC3)
|
Distinguishes hepatocellular carcinoma from non-neoplastic liver |
| gp100 (HMB-45) |
Melanoma |
| gp200 renal tubular antigen |
Not currently available |
| Granzyme |
Not offered; see TIA-1 |
| Growth hormone |
Subset of pituitary tumors |
| H |
|
| Hairy cell leukemia |
(DBA.44) Hairy cell leukemia |
| HBME-1 |
Mesothelioma, thyroid carcinoma |
| HCG |
See Chorionic gonadotropin |
| Helicobacter pylori |
Positive identification of Helicobacter |
| Hemoglobin |
Erythroid marker |
| Hepatitis B core Ag |
Hepatitis B virus identification |
| Hepatitis B surface Ag |
Hepatitis B virus identification |
| HepPar1 Antigen |
Hepatocellular and hepatoid carcinomas |
| HER2 by FISH |
Poor prognostic factor, predictor of treatment response in breast carcinoma |
| HER2 by IHC |
Poor prognostic factor, predictor of treatment response in breast carcinoma |
| HER2 HercepTest™ |
Poor prognostic factor, predictor of treatment response in breast carcinoma |
| Herpes virus |
HSVI, HSVII identification |
| HHV8 (human Herpes virus 8) |
Kaposi sarcoma, HIV-related lymphomas |
| HMB-45 antigen |
(gp100) melanoma |
| hMLH1 |
See MLH1 |
| hMSH2 |
See MSH2 |
| hMSH6 |
See MSH6 |
| hPMS2 |
See PMS2 |
| HPV |
Not offered, see p16 |
| I |
|
| IgA |
Subset of myeloma: also for skin immunofluorescence studies* |
| IgD |
Subset of myeloma: also for skin immunofluorescence studies* |
| IgG |
Subset of myeloma: also for skin immunofluorescence studies* |
| IgM |
Subset of myeloma: also for skin immunofluorescence studies* |
| Inhibin-alpha |
Granulosa cell tumors, adrenal cortical tumors |
| Insulin |
Subset of pancreatic islet cell tumors |
| J |
|
| JC virus (Jamestown Canyon) |
see SV40 |
| K |
|
| Kappa light chains |
Myeloma, some B cell lymphomas |
| Ki-1 antigen (CD30) |
Hodgkin lymphoma, anaplastic large cell lymphoma, embryonal carcinoma |
| Ki-67 antigen |
Cell proliferation marker (non-GO) |
| L |
|
| Lambda light chains |
Myeloma, some B cell lymphomas |
| Legionella |
Legionella identification |
| Leutinizing hormone |
Subset of pituitary tumors |
| Lysozyme |
Granulocytes & histocytes, marker of leukemias |
| M |
|
| Macrophage |
(HAM56) macrophage |
| Mammaglobin |
Breast cancer marker |
| MART-1 antigen |
(Melan A) Melanoma, adrenal cortical and ovarian stromal tumors |
| Maspin |
Myoepithelial marker. This antibody will be of use in a panel of other antibodies to determine the presence of invasive breast carcinoma. |
| Melanoma specific antigen |
(gp100 as identified by HMB-45) Melanoma |
| Mesothelin |
Ovarian (serous papillary) carcinoma, mesothelioma, pancreatic carcinomas |
| Mitochondria |
Oncocytomas |
| Microphthalmia transcription factor |
See MTF |
| MLH1 |
(Mismatch repair gene product) Subset of colorectal CA w/MSI |
| MOC-31 |
Adenocarcinoma related antigen, negative on mesotheliomas |
| MSH2 |
(Mismatch repair gene product) Subset of colorectal CA w/MSI |
| MSH6 |
(Mismatch repair gene product) Subset of colorectal CA w/MSI |
| MSI |
See MLH1, MSH2, MSH6, PMS2 |
| MTF |
(Microphthalmia transcription factor) Melanoma and melanocytic tumors |
| MUM1 |
Lymphoid/plasma cell specific marker |
| Muscle specific actins |
(HHF-35) Smooth, skeletal muscle differentiation: leiomyosarcoma, rhabdomyosarcoma, myofibroblasts, myoepithelium |
| Myeloperoxidase |
Granulocytes and histocytes, marker of leukemias |
| MyoD1 |
Rhabdomyosarcoma |
| Myogenin |
Rhabdomyosarcoma |
| Myoglobin |
Rhabdomyosarcoma |
| N |
|
| NB84 antigen |
Neuroblastoma and other small, blue round cell tumors |
| NCAM (CD56) |
Natural killer cells (NK/T cell lymphoma), neural tumors |
| NGFR |
Nerve growth factor receptor (p75-NTR); nerve sheath differentiation |
| Neurofilaments |
Neurons and neuronal tumors |
| O |
|
| Oct-2 |
B-cell transcription factor |
| P |
|
| p16 |
Evaluation of cervical intraepithelial lesions |
| p21-WAF1 |
Tumor suppressor gene |
| p53 |
Tumor suppressor gene product overexpressed in subset of malignancies - marker of p53 mutation and poor prognosis |
| p57 |
Distinction between complete and partial hydatidiform moles |
| p63 |
Myoepithelial marker, in situ v. infiltrating breast carcinoma; squamous, transitional cell marker; lost in prostatic adenocarcinomas |
| p75-NTR |
Nerve growth factor receptor: nerve sheath differentiation |
| p80 (ALK protein) |
Anaplastic large cell lymphoma [subset with t(2;5)] |
| p504s (Human AMACR) |
Prostate carcinoma marker |
| Pancreatic polypeptide |
Subset of pancreatic islet cell tumors |
| Parathormone |
See PTH |
| Parvovirus |
Parvovirus identification |
| PAX-2 |
Renal cell carcinoma |
| PAX-5 |
B cell specific activator protein (BSAP) |
| Pemphigoid (Bullous) |
Assessment of circulating antibodies using indirect immunofluorescence on monkey esophagus |
| Pemphigus (Vulgaris) |
Assessment of circulating antibodies using indirect immunofluorescence on monkey esophagus |
| Placental lactogen |
Intermediate trophoblasts |
| PLAP |
(Placental alkaline phosphatase) Seminoma |
| PMS2 |
DNA mismatch repair protein. This antibody will be of use in a panel of other antibodies to determine the presence of microsatellite instability. |
| Pneumocystis |
Pneumocystis identification |
| Podoplanin |
Lymphatic endothelium marker, distinguishes mesothelioma v. adenocarcinoma |
| Polyomavirus |
see SV40 |
| Prealbumin |
(Transthyretin) Choroid plexus tumors, some forms of amyloid |
| Progesterone receptor (PR) |
Breast (prognostic and predictive marker), meningiomas |
| Prolactin |
Subset of pituitary tumors |
| Prostate specific antigen |
(PSA) Prostate carcinoma |
| Prostatic acid phosphatase |
(PAP) Prostate carcinoma |
| PTH |
Parathyroid tissue and tumors |
| PS2 |
Estrogen inducible protein |
| R |
|
| Renal cell carcinoma (gp200) |
Not currently available |
| Respiratory syncytial virus |
RSV identification |
| S |
|
| S-100 |
Melanoma, Schwann cells, neural support cells, Langerhans histiocytes |
| Serotonin |
Subset of carcinoid tumors |
| SMMHC |
(Smooth muscle myosin heavy chain) Myoepithelial marker; in situ vs. infiltrating breast carcinoma |
| Somatostatin |
Subset of pancreatic islet cell & other neuroendocrine tumors |
| Surfactant ApoA1 |
Lung non-small cell carcinoma marker |
| SV40 virus |
SV40 virus identification, PML; cross reacts with BK virus, JC virus, and polyomavirus |
| Synaptophysin |
Neuroendocrine differentiation (e.g., sm. cell CA), neuroblastoma |
| T |
|
| TCR-βF1 |
α-β T cells, and most neoplasms of these cells |
| TdT |
Lymphoblastic lymphoma |
| TFE3 |
Marker of alveolar soft part sarcoma and t(X;17) renal carcinomas |
| Thrombomodulin |
Mesothelioma |
| Thymidylate synthase |
Prognostic and predictive marker in GI and other carcinomas |
| Thyroglobulin |
Thyroid follicular tumors |
| Thyroid stimulating hormone |
Subset of pituitary tumors |
| TIA-1 |
(Cytotoxic granule protein) Anaplastic large cell lymphoma |
| Topoisomerase IIα |
Predictor of treatment response |
| Toxoplasma |
Positive identification of toxoplasma |
| TRAcP |
(Tartrate resistant acid phosphatase) Hairy cell leukemia |
| Transthyretin |
(Prealbumin) Choroid plexus tumors, some forms of amyloid |
| Tryptase |
Markers of mast cells and mast cell tumors |
| TTF-1 |
(Thyroid transcription factor-1) Lung and thyroid carcinomas |
| Type IV collagen |
Basement membrane protein, subset of mesenchymal tumors |
| Tyrosinase |
Melanoma |
| U |
|
| Uroplakin |
Urothelial carcinoma |
| V |
|
| Varicella-zoster |
Positive identification of varicella- zoster |
| VEGF |
Prognostic marker and target for anti-angiogenesis therapy |
| Villin |
Adenocarcinoma subset, especially gastrointestinal |
| Vimentin |
Sarcomas, lymphomas, coexpressed with cytokeratin in some carcinomas (e.g., renal cell and endometrial carcinomas) |
| VIP |
(Vasoactive intestinal polypeptide) Subset of neuroendocrine tumors |
| von Willebrand factor |
(F. VIII related antigen) Endothelial cells, megakaryocytes |
| W |
|
| WT-1 |
(Wilms tumor gene product) desmoplastic small round cell tumor, mesothelioma, ovarian surface epithelial tumors |
| Z |
|
| ZAP-70 |
T cell marker, prognostic marker in CLL/SLL |
| Flow Cytometry "Tube" |
Antigens Evaluated |
| Mature B cell tube |
CD45, CD19, surface kappa & lambda, CD20, CD5, CD10, CD38, CD56 |
| CLL/SLL/Mantle cell lymphoma add-on |
CD45, CD19, CD5, FMC7, CD23, CD38, ZAP-70 |
| Hairy cell leukemia add-on |
CD45, CD19, CD103, CD25, CD11c, CD22, CD20 |
| Follicular lymphoma/Burkitt lymphoma add-on |
CD45, CD19, bcl-2, CD20, CD10, CD38, CD5 |
| Plasma cell neoplasm |
CD45, cytoplasmic kappa & lambda, CD19, CD38, CD56, CD20 |
| Mature T cell tube |
CD45, CD3, CD2, CD4, CD5, CD7, CD8, CD34, CD56 |
| T cell therapy add-on |
CD45, CD3, CD52, CD30, CD25, CD4, CD8 |
| T cell receptor subtype add-on |
TCR-α, TCR-β, CD5, CD4, CD8 |
| T cell clonality |
24 TCR-β isoforms, CD3, CD4, CD8, other T cell antigens as needed |
| NK cell clonality add-on |
CD158a, CD158b, & CD158e (in 3 separate tubes); each tube also contains CD3, CD7, CD16 |
| Precursor B lymphoblastic lymphoma/leukemia |
TdT, CD22, CD34, CD13, CD33, HLA-DR, in addition to antigens in mature B cell tube above |
| Precursor T lymphoblastic lymphoma/leukemia |
TdT, CD1a, CD34, CD13, CD33, HLA-DR, in addition to antigens in mature T cell tube above |
| Myeloid stem cell neoplasm (3 tubes) |
CD45, CD15, CD33, CD34, CD117, CD38, CD71, CD19, HLA-DR, CD64, CD13, CD14, CD123, CD16, CD2, CD3, CD4, CD5, CD7, CD8, CD56 |
| Acute myeloid leukemia |
3 myeloid stem cell tubes plus additional blast antigens (CD9, CD133, CD90); megakaryocytic antigens (CD41, CD61) evaluated as needed |
| Cytoplasmic lineage add-on (if blast lineage is uncertain) |
CD45, CD34, cytoplasmic myeloperoxidase, CD3, CD79a |
| Paroxysmal nocturnal hemoglobinuria (PNH) |
CD45, CD59 (erythrocytes), CD14 (monocytes), CD66b (neutrophils) |
| Small blue round cell tumors (favor non-hematopoietic) |
CD45, EpCAM (epithelial cell adhesion marker), CD99, CD90, CD56, CD10, CD38, CD3, CD19 |
This is a menu of probes available at PhenoPath Laboratories for clinical in situ hybridization studies. Our collection of available probes continues to expand; please contact us if there is a probe that you are unable to locate. Please note that this list does not include probes available for research studies.
version of this page is also available.